The MarketWatch News Department was not involved in the creation of this content. SAN CARLOS, Calif., Jan. 6, 2026 /PRNewswire/ -- Aperture Therapeutics, a biotechnology company pioneering ...
SAN CARLOS, Calif., Jan. 6, 2026 /PRNewswire/ -- Aperture Therapeutics, a biotechnology company pioneering next-generation precision medicines for neurodegenerative diseases, today announced the ...
Background The coexistence of amyotrophic lateral sclerosis (ALS) with clinical forms of Parkinson disease (PD), although uncommon, is found to a greater degree than one would expect by chance. The ...
Using machine learning models, researchers at Michigan Medicine have identified a potential way to diagnose amyotrophic lateral sclerosis, or ALS, earlier from a blood sample, a study suggests. The ...
WASHINGTON, Dec. 4, 2025 /PRNewswire/ -- I AM ALS celebrates promising new analyses released by Clene Nanomedicine demonstrating significant improvements in survival associated with their treatment, ...
Webcast set for 8:30 a.m. ET on December 3rd SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene ...
SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage ...
SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage ...
Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results